|RNA Polymerase II Regulates Topoisomerase 1 Activity to Favor Efficient Transcription|
L Baranello, D Wojtowicz, K Cui, BN Devaiah, HJ Chung, KY Chan-Salis, ...
Cell 165 (2), 357-371, 2016
|Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening|
GL Lin, KM Wilson, M Ceribelli, BZ Stanton, PJ Woo, S Kreimer, EY Qin, ...
Science translational medicine 11 (519), eaaw0064, 2019
|Targeting the AKT pathway in glioblastoma|
K McDowell, G Riggins, G Gallia
Current Pharmaceutical Design, 2011
|An OpenData portal to share COVID-19 drug repurposing data in real time|
KR Brimacombe, T Zhao, RT Eastman, X Hu, K Wang, M Backus, ...
|Drug repurposing screen for compounds inhibiting the cytopathic effect of SARS-CoV-2|
CZ Chen, P Shinn, Z Itkin, RT Eastman, R Bostwick, L Rasmussen, ...
Frontiers in Pharmacology, 2005, 2021
|Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress|
A Thomas, N Takahashi, VN Rajapakse, X Zhang, Y Sun, M Ceribelli, ...
Cancer cell 39 (4), 566-579. e7, 2021
|Reduced cortical BDNF expression and aberrant memory in Carf knock-out mice|
KA McDowell, AN Hutchinson, SJE Wong-Goodrich, MM Presby, D Su, ...
The Journal of Neuroscience 30 (22), 7453-7465, 2010
|Targeting ACE2–RBD interaction as a platform for COVID-19 therapeutics: Development and drug-repurposing screen of an AlphaLISA proximity assay|
QM Hanson, KM Wilson, M Shen, Z Itkin, RT Eastman, P Shinn, MD Hall
ACS Pharmacology & Translational Science 3 (6), 1352-1360, 2020
|Matrix screen identifies synergistic combination of PARP inhibitors and nicotinamide phosphoribosyltransferase (NAMPT) inhibitors in Ewing sarcoma|
CM Heske, MI Davis, JT Baumgart, K Wilson, MV Gormally, L Chen, ...
Clinical Cancer Research 23 (23), 7301-7311, 2017
|Overcoming adaptive therapy resistance in AML by targeting immune response pathways|
K Melgar, MM Walker, LQM Jones, LC Bolanos, K Hueneman, ...
Science translational medicine 11 (508), eaaw8828, 2019
|Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin’s lymphoma|
W Ju, M Zhang, KM Wilson, MN Petrus, RN Bamford, X Zhang, R Guha, ...
Proceedings of the National Academy of Sciences 113 (6), 1624-1629, 2016
|The transcription factor CaRF limits NMDAR‐dependent transcription in the developing brain|
MR Lyons, LF Chen, JV Deng, C Finn, AR Pfenning, A Sabhlok, ...
Journal of neurochemistry, 2016
|Large-scale pharmacological profiling of 3D tumor models of cancer cells|
LA Mathews Griner, X Zhang, R Guha, C McKnight, IS Goldlust, ...
Cell death & disease 7 (12), e2492-e2492, 2016
|Establishment and Biological Characterization of a Panel of Glioblastoma Multiforme (GBM) and GBM Variant Oncosphere Cell Lines|
ZA Binder, KM Wilson, V Salmasi, BA Orr, CG Eberhart, IM Siu, M Lim, ...
PLoS One 11 (3), e0150271, 2016
|Targeting AML-associated FLT3 mutations with a type I kinase inhibitor|
LQM Jones, K Melgar, L Bolanos, K Hueneman, MM Walker, JK Jiang, ...
The Journal of clinical investigation 130 (4), 2017-2023, 2020
|High-throughput screening identifies candidate drugs for the treatment of recurrent respiratory papillomatosis|
F Alkhilaiwi, S Paul, D Zhou, X Zhang, F Wang, N Palechor-Ceron, ...
Papillomavirus Research 8, 100181, 2019
|Mutation profiles in glioblastoma 3D oncospheres modulate drug efficacy|
KM Wilson, LA Mathews-Griner, T Williamson, R Guha, L Chen, P Shinn, ...
SLAS TECHNOLOGY: Translating Life Sciences Innovation 24 (1), 28-40, 2019
|A High-Throughput Screen Identifies 2, 9-Diazaspiro [5.5] Undecanes as Inducers of the Endoplasmic Reticulum Stress Response with Cytotoxic Activity in 3D Glioma Cell Models|
NJ Martinez, G Rai, A Yasgar, WA Lea, H Sun, Y Wang, DK Luci, ...
PloS one 11 (8), e0161486, 2016
|Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor–Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer|
TT Huang, E Brill, JR Nair, X Zhang, KM Wilson, L Chen, CJ Thomas, ...
Cancer research 80 (23), 5380-5392, 2020
|Overcoming acquired epigenetic resistance to BTK inhibitors|
AL Shaffer III, JD Phelan, JQ Wang, DW Huang, GW Wright, M Kasbekar, ...
Blood cancer discovery 2 (6), 630, 2021